Prometheus Laboratories Inc. Patent applications |
Patent application number | Title | Published |
20130237436 | DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer. | 09-12-2013 |
20130143215 | Methods of Predicting Methotrexate Efficacy and Toxicity - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient. | 06-06-2013 |
20130045880 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 02-21-2013 |
20120329172 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES - The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug. | 12-27-2012 |
20120315630 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of novel IBS biomarkers identified herein. | 12-13-2012 |
20120295280 | CITRULLINATED PEPTIDES FOR DIAGNOSING AND PROGNOSING RHEUMATOID ARTHRITIS - The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided. | 11-22-2012 |
20120277109 | PROXIMITY-MEDIATED ASSAYS FOR DETECTING ONCOGENIC FUSION PROTEINS - The present invention provides antibody-based arrays for detecting the activation state and/or total amount of one or a plurality of oncogenic fusion proteins in a biological sample such as whole blood or tumor tissue and methods of use thereof. In certain instances, the activation state and/or total amount of oncogenic fusion protein(s) present in a sample can be measured in combination with one or a plurality of signal transduction molecules. The compositions and methods of the present invention have the advantages of specificity associated with enzyme-linked immunosorbent assays, sensitivity associated with signal amplification, and high-throughput multiplexing associated with microarrays. | 11-01-2012 |
20120270745 | DRUG SELECTION FOR CANCER THERAPY BY PROFILING SIGNAL TRANSDUCTION PROTEINS IN ASCITES OR PLEURAL EFFLUX SAMPLES - The present invention provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a gastric cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from an ascites sample. The present invention also provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a lung cancer such as a non-small cell lung cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from a pleural efflux sample. | 10-25-2012 |
20120244558 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 09-27-2012 |
20120231965 | DRUG SELECTION FOR COLORECTAL CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. | 09-13-2012 |
20120171672 | INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery. | 07-05-2012 |
20110281748 | DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer. | 11-17-2011 |
20110275097 | DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 11-10-2011 |
20110244465 | METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY - The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects. | 10-06-2011 |
20110218956 | METHODS OF DIAGNOSING INFLAMMATORY BOWEL DISEASE - The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions. | 09-08-2011 |
20110159521 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 06-30-2011 |
20110071042 | BIOMARKERS FOR DETERMINING SENSITIVITY OF BREAST CANCER CELLS TO HER2-TARGETED THERAPY - The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 03-24-2011 |
20110045476 | INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery. | 02-24-2011 |
20100317022 | METHODS OF DIAGNOSING TISSUE FIBROSIS - The present invention provides a method of diagnosing the presence or severity of tissue fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of tissue fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1. | 12-16-2010 |
20100203539 | METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS - The present invention provides methods for determining a level of methotrexate polyglutamates (MTXPGs) in an individual undergoing methotrexate (MTX) therapy and for optimizing dose efficacy of MTX therapy in an individual by genotyping the individual at a polymorphic site in at least one folate pathway gene (e.g., a reduced folate carrier (RFC-1) gene, a gamma glutamyl hydrolase (GGH) gene, etc.). Methods are also provided for determining a level of MTXPGs in an individual undergoing MTX therapy and for optimizing dose efficacy of MTX therapy in an individual by generating a pharmacogenetic index based upon the genotype of the individual at a polymorphic site in an RFC-1 gene and/or a GGH gene. | 08-12-2010 |
20100203508 | METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient. | 08-12-2010 |
20100203507 | METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient. | 08-12-2010 |
20100167945 | DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 07-01-2010 |
20100129838 | METHODS FOR PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) USING SEROLOGIC MARKERS - The present invention provides methods, systems, and code for accurately classifying whether a sample from a pediatric individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from a pediatric individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions. | 05-27-2010 |
20100094560 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions. | 04-15-2010 |
20100022408 | ADDRESSABLE ANTIBODY ARRAYS AND METHODS OF USE - Systems and assay methods are disclosed for detecting an autoantibody in a sample. In certain instances, the systems and methods employ a mass tag releasably connected to an antigen. The tag is thereafter released for detection. A tag can be detected by mass spectrometry or in certain instances the tag is fluorescent. Methods for diagnosing a disease or disorder in a subject are also disclosed. | 01-28-2010 |
20090035792 | DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 02-05-2009 |
20080261829 | ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS - The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies. | 10-23-2008 |